Search

Repligen Corp

Cerrado

SectorSanidad

167.69 1.09

Resumen

Variación precio

24h

Actual

Mínimo

167.01

Máximo

168.35

Métricas clave

By Trading Economics

Ingresos

-43M

-38M

Ventas

5.2M

209M

P/B

Media del Sector

243.473

68.089

BPA

0.53

Margen de beneficios

-18.361

Empleados

2,000

EBITDA

-48M

-2M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+25.33% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-546K

11B

Apertura anterior

166.6

Cierre anterior

167.69

Repligen Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 nov 2026, 21:07 UTC

Repligen Corporation shares fell significantly, reaching a low of nearly 4.3% before slightly recovering, amid broader market trends and trading below its 20-day moving average.

11 nov 2026, 21:13 UTC

Repligen Corporation shares traded modestly lower during after-market hours on Wednesday, continuing a trend of three consecutive daily declines.

9 nov 2026, 21:03 UTC

Repligen Corporation is trading significantly higher, with a notable gain since Friday's close, and remains well above its 20-day moving average.

6 nov 2026, 21:06 UTC

Repligen Corporation's shares advanced during Friday's trading session, reflecting a notable gain since Thursday's close, despite pulling back from a midday peak.

5 nov 2026, 21:04 UTC

Correlated Moves

Repligen Corporation shares fell sharply, reflecting a broader downturn in the ARK Genomic Revolution ETF, which is facing significant losses in several holdings.

4 nov 2026, 21:21 UTC

Repligen Corporation's shares declined in after-market trading, retreating from a brief peak at Wednesday's close to a notable low within its one-month trading range.

3 nov 2026, 21:07 UTC

Correlated Moves

Repligen Corporation shares are higher, supported by a rise in Revvity, Inc. following its strong third-quarter results that exceeded analyst expectations.

2 nov 2026, 21:09 UTC

Correlated Moves

Repligen Corporation shares are declining amid a broader market downturn, trading well below their 20-day moving average following an early spike that quickly reversed.

30 oct 2026, 20:03 UTC

News

Repligen Corporation announced a $1 billion issuance of Convertible Senior Notes due 2031, with plans to repurchase shares using $120 million of the proceeds.

29 oct 2026, 20:02 UTC

Repligen Corporation shares are advancing, remaining significantly above their 20-day moving average and near the upper end of their one-month range.

28 oct 2026, 23:03 UTC

Repligen Corporation is advancing in after-market trading, showing strong performance since Wednesday's close and trading near the upper end of its one-month range.

27 oct 2026, 20:01 UTC

News

Repligen Corporation reported Q3 adjusted EPS of $0.53 and revenue of $209.31 million, while narrowing FY 2026 EPS guidance amid a $38.4 million loss.

26 oct 2026, 20:07 UTC

Correlated Moves

Repligen Corp shares are higher, following an upward trend in Charles River Laboratories, which is benefiting from positive developments in its product pipeline.

23 oct 2026, 19:16 UTC

Repligen Corp shares are declining, having pulled back from earlier gains and currently trading significantly below their 20-day moving average.

22 oct 2026, 20:07 UTC

Correlated Moves

Repligen Corp shares are declining amid a broader downturn in the Life Sciences Tools & Services sector, pulling back from earlier session highs.

21 oct 2026, 20:07 UTC

Correlated Moves

Repligen Corp's shares are advancing, regaining momentum after an earlier pullback, alongside a broader market rise and notable trading activity in Charles River Laboratories.

20 oct 2026, 20:08 UTC

Repligen Corp shares are advancing, continuing a trend higher since Monday's close, despite earlier pulling back from a session high.

19 oct 2026, 19:36 UTC

News

Canaccord Genuity raises Repligen Corp's price target to $180.00 from $145.00 while maintaining a Hold rating, reflecting a positive reassessment of the company's value.

16 oct 2026, 22:01 UTC

Repligen Corp is trading lower in after-market hours, following a notable decline since Friday's close amid unusual volatility and positioning near its one-month range low.

15 oct 2026, 20:07 UTC

Repligen Corp shares advanced, reaching a peak before the session's conclusion.

14 oct 2026, 20:07 UTC

Repligen Corp shares are advancing, benefiting from broader market gains, despite pulling back from earlier session highs. The stock is higher since Tuesday's close.

13 oct 2026, 20:07 UTC

News

Repligen Corp shares are advancing as the company prepares to report its third-quarter 2026 financial results on October 27, 2026.

12 oct 2026, 21:03 UTC

Repligen Corp shares advanced during after-market hours on Monday, moving from a low return to a high return.

9 oct 2026, 20:01 UTC

Repligen Corp shares are sharply higher, continuing an upward trajectory since Thursday's close, supported by positive movement in the broader life sciences sector.

8 oct 2026, 20:07 UTC

Repligen Corp shares fell sharply, continuing a downward trend with three consecutive sessions down, despite a brief recovery earlier in the session.

7 oct 2026, 20:01 UTC

News

Repligen Corp. finalized its $1.5 billion acquisition of BioLife Solutions, but shares fell sharply amid ongoing declines following a prior session drop.

6 oct 2026, 21:01 UTC

Repligen Corp's shares traded modestly higher in after-market hours, marking a peak since Tuesday's close despite remaining below the 20-day moving average.

5 oct 2026, 22:15 UTC

News

Repligen Corp plans to acquire BioLife Solutions, contributing to a modest after-market hours gain as the stock remains above its 20-day moving average.

2 oct 2026, 20:07 UTC

Repligen Corp's shares are advancing, reflecting a broader market trend, maintaining strong performance above the 20-day moving average amid notable intraday volatility.

1 oct 2026, 20:02 UTC

Repligen Corp shares fell sharply, breaking a trend of higher daily closes and diverging from recent upward momentum.

Comparación entre iguales

Cambio de precio

Repligen Corp previsión

Precio Objetivo

By TipRanks

25.33% repunte

Estimación a 12 Meses

Media 210.286 USD  25.33%

Máximo 235 USD

Mínimo 180 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Repligen Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

7

Comprar

1

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Repligen Corp

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
help-icon Live chat